1. The use of the anti-malaria drug Fansidar (pyrimethamine and sulphadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency
- Author
-
Christian Demanet, Jaques Otten, Nadine Balduck, Marleen Bakkus, Brigitte Desprechins, Kris Thielemans, Jutte van der Werff ten Bosch, Hendrik De Raeve, Physiology, Hematology, Pathology/molecular and cellular medicine, Pediatrics, Immunology and Microbiology, Basic (bio-) Medical Sciences, and Laboratory of Molecullar and Cellular Therapy
- Subjects
Sulfadoxine ,medicine.medical_treatment ,Lymphoproliferative disorders ,Autoimmune Diseases ,Antimalarials ,medicine ,Humans ,fas Receptor ,Autoimmune disease ,Chemotherapy ,business.industry ,Infant ,Hematology ,Syndrome ,Fas receptor ,medicine.disease ,Lymphoproliferative Disorders ,Drug Combinations ,Antigens, CD95 ,Pyrimethamine ,Apoptosis ,Autoimmune lymphoproliferative syndrome ,Immunology ,business ,Tomography, X-Ray Computed ,medicine.drug - Abstract
Fas is a protein that plays a major role in the apoptotic mechanism of several cell types, including white blood cells (WBC). Mutations of the Fas gene in humans are known to lead to autoimmune lymphoproliferative syndrome (ALPS). Glucocorticoids or cytostatic drugs are sometimes used to treat the lymphoproliferation in these patients. When treated with the anti-malaria drug Fansidar®, a patient with ALPS showed a marked shrinkage of the lymph node masses, decrease in peripheral blood lymphocytes (PBL) and an increase in neutrophil numbers. In addition, an increased Fas expression was seen on all types of leucocytes.
- Published
- 1998